{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:49:16Z","timestamp":1790704156107,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s43032-022-01061-3","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T18:03:00Z","timestamp":1660327380000},"page":"1065-1073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Sitagliptin on Metabolic Indices and Hormone Levels in Polycystic Ovary Syndrome: a Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Lijuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-2119","authenticated-orcid":false,"given":"Airong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuliu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"crossref","unstructured":"Dapas M, and Dunaif A, Deconstructing a syndrome: genomic insights into PCOS causal mechanisms and classification [published online ahead of print, 2022 Jan 13]. Endocr Rev.\u00a02022; bnac001.","DOI":"10.1210\/endrev\/bnac001"},{"issue":"3","key":"1061_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00404-020-05951-2","volume":"303","author":"S Abraham Gnanadass","year":"2021","unstructured":"Abraham Gnanadass S, DivakarPrabhu Y, ValsalaGopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet. 2021;303(3):631\u201343.","journal-title":"Arch Gynecol Obstet"},{"key":"1061_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116940","volume":"236","author":"J Wang","year":"2019","unstructured":"Wang J, et al. Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome. Life Sci. 2019;236: 116940.","journal-title":"Life Sci"},{"issue":"1","key":"1061_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s13063-022-06377-8","volume":"23","author":"J Zhao","year":"2022","unstructured":"Zhao J, et al. Comparative effectiveness of aerobic exercise versus Yi Jin Jing on ovarian function in young overweight\/obese women with polycystic ovary syndrome: study protocol for a randomized controlled trial. Trials. 2022;23(1):459.","journal-title":"Trials"},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsbmb.2018.04.008","volume":"182","author":"S Patel","year":"2018","unstructured":"Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27\u201336.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"1061_CR6","first-page":"529","volume":"93","author":"M Liu","year":"2020","unstructured":"Liu M, Murthi S, Poretsky L. Polycystic ovary syndrome and gender identity. Yale J Biol Med. 2020;93(4):529\u201337.","journal-title":"Yale J Biol Med"},{"issue":"2","key":"1061_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228586","volume":"15","author":"M Parker","year":"2020","unstructured":"Parker M, et al. Adherence to treatment for polycystic ovarian syndrome: a systematic review. PLoS ONE. 2020;15(2): e0228586.","journal-title":"PLoS ONE"},{"key":"1061_CR8","doi-asserted-by":"publisher","first-page":"204201882198923","DOI":"10.1177\/2042018821989238","volume":"12","author":"MA Abdalla","year":"2021","unstructured":"Abdalla MA, et al. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Ther Adv Endocrinol Metab. 2021;12:2042018821989238.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1061_CR9","doi-asserted-by":"crossref","unstructured":"Zeng DK, et al. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. Biosci Rep. 2019;39(7):BSR20190980.","DOI":"10.1042\/BSR20190980"},{"issue":"12","key":"1061_CR10","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632\u20137.","journal-title":"Diabetes Care"},{"issue":"12","key":"1061_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.tem.2020.09.002","volume":"31","author":"D Daneshjou","year":"2020","unstructured":"Daneshjou D, et al. Sitagliptin\/metformin: a new medical treatment in polycystic ovary syndrome. Trends Endocrinol Metab. 2020;31(12):890\u20132.","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"1061_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/cen.13444","volume":"87","author":"S Blauschmidt","year":"2017","unstructured":"Blauschmidt S, et al. Dipeptidyl peptidase 4 serum activity and concentration are increased in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87(6):741\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1061_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1210\/clinem\/dgz028","volume":"105","author":"JK Devin","year":"2020","unstructured":"Devin JK, et al. Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2020;105(1):136\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1061_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/EP-2017-0027","volume":"24","author":"S Ferjan","year":"2018","unstructured":"Ferjan S, Janez A, Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocr Pract. 2018;24(1):69\u201377.","journal-title":"Endocr Pract"},{"issue":"11","key":"1061_CR15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","volume":"33","author":"KR Richard","year":"2011","unstructured":"Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609\u201329.","journal-title":"Clin Ther"},{"issue":"11","key":"1061_CR16","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","volume":"49","author":"I Raz","year":"2006","unstructured":"Raz I, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564\u201371.","journal-title":"Diabetologia"},{"issue":"13","key":"1061_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/archinternmed.2010.188","volume":"170","author":"S Desai","year":"2010","unstructured":"Desai S, et al. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010;170(13):1169\u201371.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1061_CR18","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/j.ijcard.2013.07.257","volume":"168","author":"H Hamasaki","year":"2013","unstructured":"Hamasaki H, Yanai H. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J Cardiol. 2013;168(3):e106.","journal-title":"Int J Cardiol"},{"issue":"8","key":"1061_CR19","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.2337\/dc12-0574","volume":"35","author":"AR Gosmanov","year":"2012","unstructured":"Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012;35(8):e60.","journal-title":"Diabetes Care"},{"key":"1061_CR20","doi-asserted-by":"crossref","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41\u20137.","DOI":"10.1093\/humrep\/deh098"},{"key":"1061_CR21","first-page":"267","volume":"21","author":"J Zawadzski","year":"1992","unstructured":"Zawadzski J. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach.\u00a0Polycystic ovary syndrome. Semin Reprod Med. 1992;21:267\u201375.","journal-title":"Semin Reprod Med."},{"key":"1061_CR22","unstructured":"Higgins J. Cochrane handbook \nfor systematic reviews of interventions \nversion 5.1.0. The Cochrane Collaboration,\u00a0 editors. Naunyn-Schmiedebergs Archiv f\u00fcr \nexperimentelle Pathologie und Pharmakologie \n2011;5:S38."},{"issue":"4","key":"1061_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"1061_CR24","doi-asserted-by":"crossref","unstructured":"Daneshjou D, et al. Sitagliptin\/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: a new alternative to metformin (a randomized trial). J Reprod Immunol. 2022;150:103499.","DOI":"10.1016\/j.jri.2022.103499"},{"issue":"2","key":"1061_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11845-020-02320-5","volume":"190","author":"D Daneshjou","year":"2021","unstructured":"Daneshjou D, et al. Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI. Ir J Med Sci. 2021;190(2):685\u201392.","journal-title":"Ir J Med Sci"},{"issue":"10","key":"1061_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/met.2017.0095","volume":"15","author":"S Ferjan","year":"2017","unstructured":"Ferjan S, Janez A, Jensterle M. Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study. Metab Syndr Relat Disord. 2017;15(10):515\u201320.","journal-title":"Metab Syndr Relat Disord"},{"issue":"12","key":"1061_CR27","first-page":"1156","volume":"43","author":"Y Yang","year":"2021","unstructured":"Yang Y, Yanming Q, Xuefang J. Effects of sitagliptin on metabolic and inflammatory markers and visceral fat in polycystic ovary syndrome patients with abnormal glucose metabolism. Ningxia Med J. 2021;43(12):1156\u20138.","journal-title":"Ningxia Med J"},{"issue":"05","key":"1061_CR28","first-page":"599","volume":"27","author":"Z Junyi","year":"2019","unstructured":"Junyi Z, Zhe G, Shuangshuang W. The clinical effect of dipeptidyl peptidase 4 inhibitor in the treatment of newly diagnosed PCOS patients and its effect on blood lipid metabolism. Chin J Fam Plan. 2019;27(05):599\u2013603.","journal-title":"Chin J Fam Plan"},{"issue":"3","key":"1061_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.beem.2018.03.008","volume":"32","author":"KA Walters","year":"2018","unstructured":"Walters KA, Bertoldo MJ, Handelsman DJ. Evidence from animal models on the pathogenesis of PCOS. Best Pract Res Clin Endocrinol Metab. 2018;32(3):271\u201381.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1061_CR30","doi-asserted-by":"crossref","unstructured":"Wolf WM, et al. The current description and future need for multidisciplinary PCOS clinics. J Clin Med. 2018;7(11):395.","DOI":"10.3390\/jcm7110395"},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.metabol.2018.11.002","volume":"92","author":"CJ Glueck","year":"2019","unstructured":"Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019;92:108\u201320.","journal-title":"Metabolism"},{"issue":"6","key":"1061_CR32","doi-asserted-by":"publisher","first-page":"101894","DOI":"10.1016\/j.jogoh.2020.101894","volume":"50","author":"S Lie Fong","year":"2021","unstructured":"Lie Fong S, Douma A, Verhaeghe J. Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): how to achieve weight loss in overweight and obese women with PCOS? J Gynecol Obstet Hum Reprod. 2021;50(6):101894.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"2","key":"1061_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40618-020-01351-0","volume":"44","author":"P Moghetti","year":"2021","unstructured":"Moghetti P, Tosi F. Insulin resistance and PCOS: chicken or egg? J Endocrinol Invest. 2021;44(2):233\u201344.","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1061_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/jog.12985","volume":"42","author":"E Bil","year":"2016","unstructured":"Bil E, et al. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obstet Gynaecol Res. 2016;42(7):837\u201343.","journal-title":"J Obstet Gynaecol Res"},{"key":"1061_CR35","doi-asserted-by":"publisher","first-page":"9240569","DOI":"10.1155\/2022\/9240569","volume":"2022","author":"Y Xu","year":"2022","unstructured":"Xu Y, Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): A review of literature. J Healthc Eng. 2022;2022:9240569.","journal-title":"J Healthc Eng"},{"key":"1061_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.metabol.2017.09.016","volume":"86","author":"P Anagnostis","year":"2018","unstructured":"Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33\u201343.","journal-title":"Metabolism"},{"issue":"4","key":"1061_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/MOL.0000000000000532","volume":"29","author":"AJ Jenkins","year":"2018","unstructured":"Jenkins AJ, Welsh P, Petrie JR. Metformin, lipids and atherosclerosis prevention. Curr Opin Lipidol. 2018;29(4):346\u201353.","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"1061_CR38","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","volume":"75","author":"U Hostalek","year":"2015","unstructured":"Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071\u201394.","journal-title":"Drugs"},{"issue":"12","key":"1061_CR39","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1210\/clinem\/dgaa605","volume":"105","author":"F Andr\u00e6","year":"2020","unstructured":"Andr\u00e6 F, et al. Sustained maternal hyperandrogenism during PCOS pregnancy reduced by metformin in non-obese women carrying a male fetus. J Clin Endocrinol Metab. 2020;105(12):3762\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1061_CR40","doi-asserted-by":"publisher","first-page":"E448","DOI":"10.1210\/jc.2010-0853","volume":"95","author":"E Vanky","year":"2010","unstructured":"Vanky E, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448\u201355.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1061_CR41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.21037\/atm-22-909","volume":"10","author":"D Zhu","year":"2022","unstructured":"Zhu D, et al. Effects of metformin on pregnancy outcome, metabolic profile, and sex hormone levels in women with polycystic ovary syndrome and their offspring: a systematic review and meta-analysis. Ann Transl Med. 2022;10(7):418.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1061_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1515\/bc.2011.002","volume":"392","author":"V Matheeussen","year":"2011","unstructured":"Matheeussen V, et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem. 2011;392(3):189\u201398.","journal-title":"Biol Chem"},{"issue":"1","key":"1061_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12781","volume":"185","author":"C Klemann","year":"2016","unstructured":"Klemann C, et al. Cut to the chase: a review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1\u201321.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1061_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.22270\/jddt.v9i4-s.3261","volume":"9","author":"AV Carani","year":"2019","unstructured":"Carani AV, Dipti N. Sitagliptin recuperates oxidative stress and inflammatory cytokine expression in ovary of PCOS rats. J Drug Deliv Ther. 2019;9(4):244\u201351.","journal-title":"J Drug Deliv Ther"},{"issue":"9","key":"1061_CR45","first-page":"1559","volume":"15","author":"A Tr\u00fcmper","year":"2001","unstructured":"Tr\u00fcmper A, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol. 2001;15(9):1559\u201370.","journal-title":"Mol Endocrinol"},{"issue":"2","key":"1061_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/mmr.2022.12589","volume":"25","author":"L Lin","year":"2022","unstructured":"Lin L, Wang L. Knockdown of DPP4 promotes the proliferation and the activation of the CREB\/aromatase pathway in ovarian granulosa cells. Mol Med Rep. 2022;25(2):73.","journal-title":"Mol Med Rep."},{"issue":"3","key":"1061_CR47","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/jog.13847","volume":"45","author":"F Wang","year":"2019","unstructured":"Wang F, et al. Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor-\u03b21 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats. J Obstet Gynaecol Res. 2019;45(3):600\u20138.","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"1061_CR48","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1463-1326.2011.01362.x","volume":"13","author":"AJ Tremblay","year":"2011","unstructured":"Tremblay AJ, et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):366\u201373.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1061_CR49","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.2337\/db13-1654","volume":"63","author":"C Xiao","year":"2014","unstructured":"Xiao C, et al. Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes. 2014;63(7):2394\u2013401.","journal-title":"Diabetes"},{"issue":"2","key":"1061_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/fcp.12001","volume":"28","author":"G Derosa","year":"2014","unstructured":"Derosa G, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol. 2014;28(2):221\u20139.","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"1061_CR51","doi-asserted-by":"publisher","first-page":"e2386","DOI":"10.1097\/MD.0000000000002386","volume":"95","author":"M Fan","year":"2016","unstructured":"Fan M, Li Y, Zhang S. Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2016;95(2):e2386.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1061_CR52","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ. Sitagliptin: a review in type 2 diabetes. Drugs. 2017;77(2):209\u201324.","journal-title":"Drugs"},{"issue":"4","key":"1061_CR53","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/VHRM.S3105","volume":"4","author":"J Green","year":"2008","unstructured":"Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag. 2008;4(4):743\u201351.","journal-title":"Vasc Health Risk Manag"},{"issue":"19","key":"1061_CR54","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1080\/15384101.2019.1652036","volume":"18","author":"Q Wang","year":"2019","unstructured":"Wang Q, et al. Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19. Cell Cycle. 2019;18(19):2538\u201349.","journal-title":"Cell Cycle"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-022-01061-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-022-01061-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-022-01061-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T17:22:30Z","timestamp":1683220950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-022-01061-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1007\/s43032-022-01061-3","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"12 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}